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Institutes of Health Consensus Workshops.
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topics to decide what can be agreed upon and,
when a consensus is reached, to develop a
research agenda. The participants are then asked
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provided to the public and, finally, what messages
are pertinent to policymakers at the foundation,
business, and governmental levels. Previous 
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Preface
replacement therapy. A Men’s Health Initiative at 
the National Institutes of Health comparable to
the Women’s Health Initiative would provide
valuable information about the safety and efficacy
of male hormone replacement.
Thus far, the National Institutes of Health and
Veteran’s Administration have decided against
undertaking the large clinical trial because of
understandable concern regarding the possibility
of promoting prostate cancer. However, since
thousands of men daily appear to be willing to
take their chances on unproven hormone replace-
ment, surely they should be allowed to give
informed consent to volunteer in a randomized,
double-blind clinical trial that would answer
questions about the pros and cons of replacement
therapy on bone, muscle, sexuality, and central
nervous function, as well as its long-term safety.
A large-scale clinical study of benefits and risks
of both short- and long-term testosterone
replacement therapy conducted in multiple centers
would involve 6,000 men, examined over six years,
at a cost of over $100 million. The price is high,
but not as high, in the long run, as inaction.
Robert N. Butler, M.D.
President and CEO
International Longevity Center-USA
Ahuge national drug experiment is under way.It affects hundreds of thousands of men, it isunsupervised and uncontrolled, and its 
subjects are unaware that they are taking a drug
with unknown and potentially life-threatening side
effects. The drug is testosterone replacement,
and, increasingly, men are using it in an attempt to
regain youthful vitality, sexuality, mental alacrity,
and bone and muscle mass.
Women already have a long history of hormone
replacement therapy use, beginning in 1948 when
Robert Wilson first published Feminine Forever.
Based on theories unsupported by research,
the book nevertheless fed the fantasies of many
women (and their partners) that by ingesting an 
estrogen pill youthful femininity could be 
prolonged indefinitely. After it was reported that
women who took the hormone developed
uterine cancer in larger numbers than women who
hadn’t taken it, combined estrogen-progesterone
hormone therapy was developed, which protects the
uterus. However, it wasn’t until 50 years after
Feminine Forever was published that women had 
a comprehensive body of information about the
benefits and long-term risks of hormone replacement.
Today, men face a similar situation, but they are in
a position to learn from women’s experiences. What
is needed is a longitudinal clinical trial that
addresses the benefits and risks of testosterone 
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INTRODUCTION
As our population ages, concerns about frailty 
and disability, as well as the all-too-human desire
to remain young for as long as possible have 
led increasing numbers of women and men to the
questionable practice of restoring diminishing
hormone levels. Recent research findings have
alerted women to the potential health risks of
estrogen replacement therapy, but to date no serious
long-term studies have been conducted to examine
the effects on men of testosterone replacement.
The lack of information about testosterone should
be of particular concern because testosterone use
in this country has skyrocketed, with sales 
reaching $400 million in 2002. While men
whose testosterone levels have greatly diminished
often experience a decline in muscle mass or
strength and reduced bone mass that frequently
leads to frailty and disability, it is not known
whether testosterone replacement can delay or
prevent this loss. Nor have the long-term effects
of this hormone replacement therapy been 
studied. For example, little is known about the
effect testosterone replacement has on the risks 
of prostate and heart disease.
On May 16-19, 2002, a group of eminent
researchers gathered at Canyon Ranch Health
Resort in Tucson, Arizona. The purpose of this
consensus workshop was to determine what is
known about testosterone and the effects of
testosterone replacement therapy, to propose a
research agenda for future work, and to identify
other steps that might be taken in the realm 
of public information and policy.
It is extremely important to understand the health
risks of testosterone deficiency and whether
testosterone replacement therapy is safe and effective.
The academic community is in agreement that
large-scale definitive studies are needed to obtain
realistic estimates of the long-term clinical 
benefits and risks of testosterone replacement in
older men.
WHAT IS TESTOSTERONE?
Testosterone is a vital sex hormone that is produced
in the testes, the male reproductive glands that
also produce sperm. Testosterone is the major
determinant of male sexual differentiation in 
the fetus and male secondary characteristics and 
function in boys and men. Production of 
testosterone peaks during adolescence and early
adulthood, and it declines progressively with age
at the rate of about 1 percent per year beginning
in the fourth decade of life. The extent to which
this contributes to loss of bone, lean body/skeletal
muscle mass, gain in body fat, and frailty 
remains to be determined. Little proof exists to
support the hypothesis of andropause—the 
so-called “male menopause.” Unlike women, whose
estrogen levels precipitously decline beginning in
their fourth decade, men exhibit a large range of
normal testosterone levels throughout life.
MUSCLE MASS
A number of studies have shown an increase in
muscle mass with testosterone treatment in older
men without a concomitant increase in muscle
strength. However, doses were not consistent and
Executive Summary
Robert N. Butler, M.D.
President and CEO, International Longevity Center
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the hormone levels of many men studied were not
sufficiently diminished. It has also been suggested
that upper-limb muscles may be more sensitive
to testosterone effects than lower-limb muscles.
Carefully designed studies with consistent subjects
and dosages are needed to clarify the results.
BONE DENSITY
During puberty, bone mineral density increases
dramatically in boys. As men age, bone mineral
density declines, and they become vulnerable
to fractures. It is unclear whether this decline is 
due to age-related declines in testosterone or to 
other bone-regulating factors (e.g., parathyroid
hormone, vitamin D, growth hormone). One
study conducted to determine testosterone’s role
in increasing spinal bone density, found that only
in men whose serum testosterone levels were 
particularly low before treatment did the 
hormone therapy improve bone density. Another
study found that testosterone given to healthy
older men with low testosterone levels prevented
femoral neck bone loss, decreased body fat, and
increased lean body mass and lower-extremity
muscle strength. Although these findings suggest
that testosterone replacement may benefit some
older men, further studies are needed, particularly
studies that examine fracture rates over time.
BRAIN FUNCTION AND COGNITION 
The results of basic science investigations corrob-
orate those of clinical trials and epidemiological
studies. Although not universally confirmed,
administration of testosterone to men with low
testosterone levels has been shown to enhance
cognitive function in the majority of clinical
studies. It must be noted that this enhancement
is confined to specific areas. In several independent
studies, weekly administration of testosterone,
either by injection or scrotal patch, significantly
enhanced spatial memory, working memory, and
verbal fluency of healthy older men. Again,
findings of these clinical studies are preliminary
and need to be systematically confirmed in larger
clinical studies before the therapeutic potential 
of testosterone can be firmly established.
PROSTATE AND ERECTILE FUNCTION
One of the greatest fears of supplementing older
men with testosterone is an increased risk for
benign hyperplasia and/or prostate cancer.
Dozens of reports on prospective testosterone
replacement studies over the last 20 years have
shown no increase in prostate cancer. However,
no definitive conclusions can be drawn yet
because of methodological shortcomings of the
studies available to date. These include short
duration of follow-up; studies were not designed
to take into account that incidence of prostate
cancer is closely linked to age, race and ethnicity;
lack of consistency in evaluation of prostates
(e.g., only a few studies use biopsies of the
prostate for assessment.) Testosterone clearly
improves libido when administered to older men.
RESEARCH AGENDA
To date a number of small-scale randomized trials
of testosterone replacement therapy in older men
have been conducted with reports of positive effects
on bone mineral density, muscle strength, and
increase in lean body mass with a decrease in body
fat. However, none have included a sufficient 
number of subjects to adequately assess risks and
benefits of testosterone replacement. A large-scale
study with approximately 6,000 subjects has been
estimated as necessary to ascertain changes in the
incidence of prostate cancer and coronary events
and to firmly establish possible benefits.
Better technology is needed to determine normal
ranges of testosterone and to identify abnormally
low levels in individuals who might benefit from
testosterone replacement. The development of accu-
rate diagnostic testing would also aid in this process.
INTRODUCTION
Increasing frailty with age is a major problem for
the older American population and increases the
risk for adverse health outcomes such as falls,
hospitalization, institutionalization, and eventually
mortality (Fried et al. 2001). Unfortunately,
neither an adequate definition of nor means of
assessing frailty is available. Gillick (2001) 
suggests that frailty is “so ill-defined that some
gerontologists dispute that it is any more than a
synonym for disability.” Nevertheless, there is 
certainly consensus that a biological understanding
of what causes older persons to become frail could
provide a link between aging and the diseases 
of old age and could lead to interventions to delay
and/or prevent disability among older persons.
Such interventions are already being suggested
based on known age-related changes in levels of
circulating hormones, but most of these suggested
interventions are based on insufficient knowledge
of the full implications of the hormone replacement
therapy suggested. One of these potential 
interventions is testosterone supplementation in
older men. An epidemiological study has suggested
that declining function in old age is related to low
levels of bioavailable testosterone (Perry et al. 2000),
and a single small study found that testosterone
therapy enhanced function in older males 
undergoing rehabilitation (Bakhshi et al. 2000).
Serum testosterone levels decline with age in men,
and in some men testosterone declines to such 
a large extent as to classify these men as “hypogo-
nadal.” As observed in both cross-sectional (Gray
et al. 1991) and longitudinal (Morley et al. 1997a;
Zmuda et al. 1997; Harman et al. 2001; Feldman
et al. 2002) studies, beginning in the third decade
age is associated with a gradual and progressive
decline in serum testosterone levels at a rate of
approximately 1 percent per year. About 98 percent
of serum testosterone is either tightly bound to
sex hormone binding globulin or weakly bound to
serum albumin. Thus, only about 1 percent to 
2 percent of testosterone circulates freely in 
the plasma unbound to proteins. The bioavailable
testosterone, comprised of the free testosterone
plus the testosterone weakly bound to albumin,
is thought to be responsible for testosterone’s 
biologic effect in most tissues. Bioavailable testos-
terone declines even more with age than does
total testosterone because of a concomitant 
age-related increase in sex hormone binding globulin
(Figure 1). Men with total and/or bioavailable
testosterone levels below the normal range for
young men, are classified as “hypogonadal” (see
following section). Rather than utilize this type of
statistical construct to define hypogonadism,
workshop participants recommended that, where
possible, the definition of hypogonadism should
be based on functional as well as biochemical 
criteria, i.e., low serum levels of testosterone that
are associated with physiological changes 
consistent with androgen deficiency, such as
reduced muscle mass or strength, reduced bone
mass, etc. Such a definition would follow the
analogy of hyperlipidemia, where normal levels 
of total cholesterol (as high as 260) previously
were defined on the basis of a statistical construct
but now are based on levels associated with 
cardiovascular disease (normal levels less than
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200). Unfortunately, at the time of this report
insufficient data exist to rigorously identify levels
of testosterone that define physiological or 
functional hypogonadism for most target organs
and tissues. The participants agreed that 
priority should be given to allocating resources for
research aimed at addressing this problem.
It remains unclear what role the observed decline
in total and bioavailable testosterone plays in male
aging. Matsumoto (2002) has recently reviewed
the clinical implications of the decline in testos-
terone with aging, but the long-term clinical 
beneficial effects of testosterone replacement in
older men remain poorly defined, and its 
long-term effects on the risks of prostate and
heart disease remain largely unknown. Because of 
these uncertainties about the clinical utility of 
hormone replacement in older men, the academic 
community is in agreement that large-scale 
definitive studies are needed to obtain realistic
estimates of the long-term clinical benefits and
risks of testosterone replacement in older men.
In contrast to the academic community, the media
and the public at large appear to have moved
beyond science in this field. As a result, testos-
terone sales have been growing at an alarming rate
in the last several years. A review of prescription
sales data indicates that testosterone sales had
been steady at about $18 million until 1988.
In that year, ALZA Corporation introduced the
Testoderm scrotal testosterone patch. In 1993,
GlaxoSmithKline started marketing the
Androderm patch developed by TheraTech Inc.
Since 1993, testosterone sales have been growing
at 25 percent to 30 percent per annum, increasing
from $23 million in 1993 to $71 million in 1999.
In 2000, when Androgel‚ was introduced into 
the market, testosterone sales more than doubled
to $150 million. A recent market analysis of 
prescription sales indicates that testosterone sales
had reached $250 million in the year 2001 and
are expected to reach $400 million in 2002, based
on current projections (Anderson et al. 2002).1
These sales data refer to the dollar amount 
of prescription sales at the retail level and do not
include all the sales of the product, particularly 
at the wholesale level. Therefore, although these
sales data derived from IMS and BMC 
corporations are considered reliable and widely
used by the pharmaceutical companies for making
sales projections, they likely underestimate the
total sales volume.
This explosive growth in testosterone prescription
and usage has spawned enormous interest in the
pharmaceutical industry in developing new 
testosterone formulations. At the present time, at
least 12 different androgen formulations are in
various phases of clinical development. These
developmental efforts by the industry suggest that
the upward pressures on the sales of testosterone
products are likely to persist and even grow in the
foreseeable future. Thus, it is extremely important
for the scientific community to develop a 
consensus about the health benefits and safety of
these products. The purposes of this report are to:
(1) summarize what we already know about 
the andropause and the effects of testosterone 
replacement therapy; (2) propose a research 
agenda for future work; and (3) identify other
steps that might be taken in the realm of public 
information and policy.
WHO IS HYPOGONADAL?
The following statement about “normal”
testosterone levels is taken from the report of the
Second Annual Andropause 2001 meeting 
sponsored by the Endocrine Society. This report
is available to members of the Endocrine 
Society at www.endo-society.org/membership/
membersonly.cfm.
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1 These data and projections were provided to Dr. Bhasin 
by officials at GlaxoSmithKline, IMS Corporation, ALZA
Corporation, and Solvay-Unimed Corporation.
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“The normal range for serum total testosterone
levels in early morning hours in healthy young
men 20 to 40 years of age is approximately 
300 ng/dL to 1,000 ng/dL. The recommendations
of this Consensus Panel were predicated on this
range for normal serum testosterone. Assuming
that a patient has signs or symptoms consistent
with androgen deficiency and no contraindications
exist, men who fall below the lower limit of 
this range would likely benefit from treatment 
independent of age.
“Total testosterone levels < 200 ng/dL clearly
indicate hypogonadism, and in most instances
indicate that benefits may be derived from testos-
terone replacement therapy. Total testosterone
levels between 200 ng/dL and 400 ng/dL should
be repeated and followed up by calculation of 
free testosterone from total testosterone and 
sex-hormone binding globulin concentrations, or
by measurement of free testosterone levels by 
the dialysis method, or bioavailable testosterone
by the ammonium sulfate precipitation method.
If a healthy man has a serum testosterone 
level > 400 ng/dL, it is unlikely he is testosterone
deficient and, therefore, clinical judgment should
guide the next steps, even if he has symptoms
suggestive of testosterone deficiency.” However,
recent data suggest that an upper value of 
500 ng/dL should be used (Morley et al. 2002).
The Consensus Panel went on to conclude that
based on this definition, 49 percent of men 
over 80, 28 percent of men 70–79 years old, and 
19 percent of men 60–69 years old could be 
considered to have low total testosterone levels.
Thus, it is extremely important to understand
what the health risks of testosterone deficiency
are and whether testosterone replacement therapy
is both safe and effective. The following sections
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Effects of age on serum testosterone (left panel) and free testosterone index (right panel) in Baltimore Longitudinal Study of Aging men
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p values are also shown. Total testosterone concentrations and free testosterone index values decreased linearly with increasing age.
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of this document discuss what is known about 
the role of testosterone in various physiological
systems and what changes occur with aging.
There are three screening tests using symptoms
and/or epidemiological factors currently in use to
detect hypogonadism, i.e., androgen deficiency 
in aging males (Morley et al. 2000), Massachusetts
Male Aging Study (III) Screen (Smith et al.
2000) and the Aging Men’s Survey (Heineman 
et al. 1999). The first two tests have undergone
some degree of validation. The androgen deficiency
in aging males test has undergone independent
validation in Belgium (Legros and Delhez 2002).
There is an overwhelming need for independent
epidemiologically appropriate validation of these
questionnaires. Although androgen deficiency 
in aging males is widely utilized throughout the
world to screen for older hypogonadal men, a 
better test based on known symptoms of hypogo-
nadism is needed.
BIOCHEMISTRY AND METABOLISM 
OF TESTOSTERONE
Testosterone is a steroid hormone made from
cholesterol predominantly in the Leydig cells of
the testis via the androgen biosynthetic pathway
(Figure 2). Testosterone is the major determinant
of male sexual differentiation in the fetus and male
secondary characteristics and function in boys 
and men. The amount of testosterone synthesized
in the testis is determined largely by prevailing
plasma concentrations of luteinizing hormone (LH),
a gonadotropin secreted by the pituitary gland.
Luteinizing hormone secretion in turn is con-
trolled by feedback regulation by plasma levels of
sex steroid hormones. Serum levels of total and
free testosterone increase during puberty, reaching
a maximum in the twenties and thirties, then
generally decline steadily at about 1 percent per
year with increasing age (Figure 1). In response to
declining testosterone concentrations in blood
and reduced negative feedback, serum luteinizing
hormone levels tend to increase with aging.
However, luteinizing hormone concentrations
usually remain within the normal range as a result
of age-related reduction in the secretion of
gonadotropin-releasing hormone by the 
hypothalamus and reduced gonadotropin releasing
hormone stimulation of the pituitary gland.
The age-related decline in serum testosterone is 
due primarily to reduced testicular production of
testosterone, but inadequate luteinizing hormone
stimulation also contributes to the decline.
Metabolic clearance of testosterone also decreases
with aging attenuating the effect of reduced 
testosterone production by the testis. Finally,
serum testosterone levels are suppressed further
by comorbid conditions such as illness,
medication, and malnutrition that are often 
associated with aging.
A critical factor in evaluating the biologic effective-
ness of testosterone is the circulating concentration
of bioavailable testosterone. Bioavailable testos-
terone, the fraction of circulating testosterone that
is not tightly bound to sex hormone binding
globulin, is considered to be the biologically active
component that actually enters cells, interacts
with intracellular androgen receptors, and in 
that manner regulates gene expression and cellular
function. Like estrogen, the androgen receptor
activity is modulated by a number of intracellular
coregulators that modify the response to 
androgen in a tissue-specific manner. This rather
straightforward picture is complicated by the 
likely presence of cell membrane resident androgen
receptors that are responsible for rapid,
nongenomic effects of testosterone, and by studies
showing that sex hormone binding globulin 
itself can initiate cellular signaling when bound to
steroid hormones (Rosner et al. 1999). Sex 
hormone binding globulin levels increase with age
but decrease in response to conditions such as
moderate obesity. These and other changes in sex
hormone binding globulin levels may affect 
4
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total testosterone levels and may complicate 
their interpretation in certain clinical situations,
reinforcing the need to measure free or bioavail-
able testosterone levels using an accurate assay in
order to diagnose hypogonadism.
Testosterone is actively metabolized to estradiol, a
potent estrogen, by the enzyme aromatase and to
dihydrotestosterone, a more potent androgen 
than testosterone, by the enzymes 5α-reductase
types 1 and 2 (Figure 2). Therefore, the physio-
logical actions of testosterone may be mediated by
both testosterone and dihydrotestosterone that
interact with the androgen receptor, which is
encoded by a single gene, as far as we know now,
and estradiol, which interacts with two distinct
estrogen receptors (alpha and beta) that are the
products of two separate genes. The conversion of
testosterone to dihydrotestosterone in certain
androgen target tissues acts to amplify the actions
of testosterone and is essential for primary sexual
differentiation and growth of the external 
genitalia and prostate in the fetus and is important
in development of male hair pattern. Some other
androgen actions, such as enhanced growth and
development of skeletal muscle and bone, appear
to be less influenced by dihydrotestosterone.
Conversion of testosterone to estradiol is thought
to play an important role in mediating some of
the effects of testosterone, e.g., on bone, brain
function, and adipose tissue. Circulating levels 
of total estradiol and dihydrotestosterone do 
not change appreciably with age, but bioavailable 
fractions of these hormones decline because sex
hormone binding globulin levels increase with
aging (Khosla et al. 1998). The relative roles of
testosterone, dihydrotestosterone, and estradiol in
mediating the effects of circulating testosterone
on target tissues and biological function, especially
as a function of aging, are not well understood
and represent areas of active research.
If testosterone treatment for aging men is 
promoted on a widespread basis, an area crucial
for further research will be age-related changes 
in tissue-specific sensitivity and dose response to
testosterone, both at the molecular and clinical
level. A report using a rat model of male 
reproductive aging provides evidence that the
aging prostate becomes more sensitive to 
Figure 2
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testosterone (Banerjee et al. 1998). In contrast,
indirect evidence suggests that muscle, bone,
and central nervous system mechanisms 
mediating male libido may actually become less
sensitive to testosterone with increasing age 
in men (Tsitouras et al. 1982).
TESTOSTERONE REGULATION OF 
SKELETAL MUSCLE
A common finding of studies of hypogonadal
young men, as well as older men with age-related
declines in testosterone, is reduced lean body
mass. The observation that testosterone supple-
mentation in both young and older men increases
muscle mass suggests that testosterone may play
an important role in the preservation of muscle
mass although the underlying mechanism(s) 
is not well understood. In these studies, muscle
strength frequently does not track with muscle
mass, particularly in older subjects. Skeletal 
muscle is a very dynamic tissue, constantly under-
going muscle protein synthesis and breakdown.
Studies have shown that androgens stimulate
muscle protein synthesis in the short term 
(< six months), but chronic exposure shifts the
effect to inhibition of protein breakdown.
Androgens induce their specific response through
the androgen receptor, which in turn regulates
expression of androgen-regulated genes. A study
in exercising rats (Inoue et al. 1994) showed that
skeletal muscle growth depended on increased
androgen receptor levels. Short-term exposure to
a synthetic androgen in young men increased
expression of the androgen receptor gene
(Sheffield-Moore et al. 1999), while in older men
testosterone administration increased androgen
receptor levels at one month, but androgen 
receptor levels returned to baseline at six months
(Ferrando et al. 2002). In this same study, insulin-
like growth factor-I levels were increased by
testosterone and remained elevated at six months
while IGFBP-4 (insulin-like growth factor binding
protein) was decreased. Snyder et al. (1999a)
showed an increase in insulin-like growth 
factor levels over three years while Wittert et al.
(2002) failed to show such an increase.
A number of studies have shown an increase in
muscle mass with testosterone treatment in older
men (Tenover 1992; Katznelson et al. 1996;
Snyder et al. 1999a; Bebb et al. 2001; Wittert et
al. 2002); however, an increase in muscle strength
has been reported less commonly (Morley et al.
1993; Sih et al. 1997; Urban et al. 1995; Tenover
1996; Clague et al. 1999; Bakhshi et al. 2000;
Ferrando et al. 2002). A major reason for this is
that many studies failed to treat persons who were
clearly hypogonadal. Wittert et al. (2002) 
demonstrated that in persons who had borderline
hypogonadism there was an increase in muscle
mass but not in muscle strength. In addition,
different doses of testosterone, i.e., injection versus
patch versus oral, have been used; and Hikim 
et al. (2002) showed that the effects of testosterone
on muscle are sensitive to dose. It has also been
suggested that upper-limb muscles may be 
more sensitive to testosterone effects than are
lower-limb muscles. These discrepant results
require carefully designed studies to resolve the
differences in results.
The composition of muscle is another important
variable in assessing muscle function. Human
skeletal muscle is composed of three basic fiber
types—I, IIa, and IIx. Fiber typing is determined
by ATPase histochemical staining intensities 
and immunohistochemical analysis using antibodies
that identify myosin heavy chains (Scott et al.
2001). Type I fibers display slower contraction
rates and more oxidative physiology while type II
fibers are faster and use anaerobic metabolism.
The plasticity of muscle fibers as displayed by
their ability to convert between fiber types
depending upon the demand on the muscle is a
unique physiologic mechanism that supports 
possible interventions to optimize fiber composition
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7and muscle function (Baldwin and Haddad
2001). Examination of muscle fiber types during
aging shows a primary loss of type II fibers
(Lexell 1995; Scott et al. 2001). A similar pattern
of loss of muscle mass occurs in human muscle
during prolonged exposure to microgravity 
(Fitts et al. 2001). The loss of muscle fibers in
frail elders can be reversed by weight-lifting 
exercises (Singh et al. 1999). Regarding androgen
effects on skeletal muscle fiber type, norandrolone
administration to rats increased muscle
diaphragm size by increasing type IIa and IIx
muscle fibers (Lewis et al. 2002).
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Figure 3
Finally, the primary site of testosterone action may
not be the muscle fiber, but rather the satellite cell
or muscle stem cell. It has recently been observed
that the testosterone-induced increase in muscle
size is associated with an increased number of
satellite cells as well as hypertrophy of both type I
and II fibers. Testosterone may promote 
differentiation of a primordial stem cell into the
myogenic lineage rather than the adipocyte 
lineage (Sinha-Hikim et al. 2002). If so, this
could explain the increased age-related deposition
of fatty streaks into muscle as testosterone levels
decline. Changes in protein synthesis seen in
response to testosterone mentioned above may thus
reflect effects on stem cell differentiation pathways.
EFFECT OF TESTOSTERONE ON BONE DENSITY
Hypogonadism is a well-known risk factor for
osteoporosis in men (Leder et al. 2001), and both
surgical and medical castration reduce bone mineral
density rapidly in men (Stepan et al. 1989; Smith
et al. 2001). However, the relative roles of androgens
and estrogens in bone development and in the
maintenance of bone mass in men are unclear.
Several observations suggest that androgens have
a direct role in maintaining the skeleton. First,
osteoblasts have androgen receptors (Colvard et al.
1989). Second, bone mineral density increases
dramatically during puberty in boys, and peak
cortical bone density is higher in men than in
women (Bonjour et al. 1991). Cortical thickness
and bone formation rates are reduced in 
androgen-resistant rats (Vanderschueren et al.
1993). Finally, both aromatizable and nonaroma-
tizable androgens stimulate osteoblast activity 
and prevent castration-induced bone loss
(Kasperk et al. 1990; Van Kesteren et al. 1996).
Several observations, however, suggest that the
effects of androgens are mediated, at least in part,
by their conversion to estrogens. First, osteoblasts
have estrogen receptors as well as the ability to
convert testosterone to estrogen by the aromatase
enzyme (Eriksen et al. 1988; Tanaka et al. 1993).
Second, serum estradiol levels correlate better
with bone density than do serum testosterone 
levels (Khosla et al. 1998; Amin et al. 2000).
Orchiectomy and aromatase inhibition reduce
bone density similarly in rats (Vanderschueren et
al. 1996), and estrogen alone can maintain bone
mass in castrated male rats and people (Cruess
and Hong, 1978; Van Kesteren et al. 1996).
Perhaps the best evidence for an important role
for estrogens in bone in male humans is the finding
that men with inactivating mutations in either
the estrogen receptor gene (Smith et al. 1994) or 
the aromatase gene (Morishima et al. 1995;
Carani et al. 1997) develop osteoporosis. This
strongly suggests that estrogen plays a vital role in
achieving normal peak bone mineral density 
in men. In adult men, additional recent evidence
suggests that both androgens and estrogens play
important roles in maintaining bone homeostasis
(Falahati-Nini et al. 2000; Leder et al. 2001).
As men age, both cortical and trabecular bone
mineral density decline (Wishart et al. 1995;
Riggs et al. 1981; Zmuda et al. 2000). It is
unclear whether this decline is due to age-related
declines in either serum testosterone or estradiol,
or to other bone-regulating factors such as
parathyroid hormone, vitamin D, growth hormone,
and insulin-like growth factor (Feldman et al.
2002; Ferrini and Barrett-Connor 1998; Denti et
al. 2000; van den Beld et al. 2000) (Figure 3).
When Snyder et al. (1999b) randomly adminis-
tered transdermal testosterone or placebo to men
over age 65 with serum testosterone levels below
475 ng/dL (mean 367 ng/dL), testosterone
administration increased mean serum testosterone
levels to 625 ng/dL, but changes in spine bone
density were similar in testosterone-treated and
placebo-treated men. Only in men whose serum
testosterone levels were particularly low before
treatment (i.e., < 200 ng/dL), did it appear that
testosterone therapy improved spine bone mineral
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9density. Kenny et al. (2001) have also shown that
transdermal testosterone prevented femoral 
neck bone loss, decreased body fat, and increased
lean body mass and lower-extremity muscle
strength in healthy older men with low bioavailable
testosterone levels. Although these findings 
suggest that testosterone replacement may benefit
some elderly men, further studies, particularly
studies that examine fracture rates as an endpoint,
are needed.
TESTOSTERONE, BRAIN FUNCTION 
AND COGNITION
Similar to the situation with bone, most studies of
the effects of sex steroid hormones on brain 
function have centered on estrogen rather than
testosterone, and few of those have focused on
cognition. Testosterone, which crosses the 
blood-brain barrier easily, affects brain function
via androgen receptor selectively distributed
throughout the brain (Simerly et al. 1990).
Additionally, androgens are probably synthesized
in the brain and play an important role in its
development, growth, maturation, and differentia-
tion (Stoffel-Wagner 2001). Steroid biosynthetic
and metabolic enzymes, in particular estrogen
synthetase (aromatase), 5α-reductase, and
P450scc, are found in brain regions closely 
associated with memory and related functions
(Lephart et al. 2001). Specific neurobiological
effects of testosterone with direct relevance to
cognition include increasing serotonergic activity
in cerebral cortex and amygdala (Fink et al.
1999), choline acetyl transferase activity in the
hippocampus (Nakamura et al. 2002), and 
neurokinin and cholecytokin in amygdala and
hypothalamus, and decreasing dopamine release
in mesolimbic tract (Rubinow and Schmidt,
1996). Testosterone also attenuates β-amyloid-
induced toxicity in cultured hippocampal neurons
(Pike 2001), reduces neuronal secretion of Αβ
peptide in cultured primary cortical neurons
(Gouras et al. 2000), and promotes α-cleavage
processing of amyloid precursor protein, resulting
in the formation of soluble, nontoxic fragments
(Goodenough et al. 2000). Additionally,
testosterone improves memory in the senescence-
accelerated SAMP8 mouse, an animal model of
β-amyloid overproduction, and decreases levels 
of amyloid precursor protein in this mouse (Flood
et al. 1995). Finally, testosterone is aromatized 
to estradiol in the brain, which reportedly
enhances the activity of several neurobiological
systems closely associated with cognition
(Cholerton et al. 2002).
To date the results of basic science investigations
are nicely corroborated with those from clinical
trials and epidemiological studies. Although 
not universally confirmed, administration of
testosterone has been shown to enhance cognitive 
function in the majority of clinical studies. Of
note, the cognition-enhancing efficacy of testos-
terone is not generalized but confined to 
specific domains. For example, weekly injections 
of testosterone enanthate for four to six weeks 
in two independent studies significantly enhanced
spatial memory of healthy older men (Cherrier 
et al. 2001; Janowsky et al. 1998). Likewise,
results from another study suggested that a 
three-month administration of testosterone via
scrotal patch produced significant enhancement 
in spatial memory ( Janowsky et al. 1994). In 
addition to spatial memory, findings from clinical
studies indicated that treatment with testosterone
enhanced working memory and verbal fluency as
well ( Janowsky et al. 2000; O’Connor et al. 2001).
Data from epidemiological studies also support
the cognition-enhancing efficacy of testosterone.
Moffat et al. (2002) have shown that, in men in
the Baltimore Longitudinal Study of Aging,
higher free testosterone levels are associated with
better maintained cognition with age for some,
but not all, of the cognitive domains. Cross-
sectional studies have also suggested that higher
ILC Workshop Report: Masculine Vitality: Pros and Cons of Testosterone in Treating the Andropause
concentrations of endogenous testosterone are
associated with enhanced cognitive function in
older men (Morley et al. 1997b; Barrett-Connor
et al. 1999). Further support for a direct 
relationship between testosterone and cognition 
is provided by the reported gender-related 
differences in performance on neuropsychological
tests. Men reportedly outperform women on 
tests of visuospatial memory while women 
do better on tests of verbal fluency and perceptual
speed (Linn and Petersen 1985; Halpern 1992).
The cognition-enhancing efficacy of testosterone,
however, is not uniformly supported by findings
from all clinical studies. For example, in one 
study biweekly injections of 200 mg of testos-
terone cypionate for 12 months did not improve
performance on several tests of cognition for older
hypogonadal men (Sih et al. 1997). Similarly, a
single-dose injection of testosterone enanthate in
another study blocked the practice effects in 
verbal fluency and did not enhance performance
on any other cognitive test (Wolf et al. 2000).
Finally, data from an epidemiological study
showed no relationship between plasma levels of
testosterone and spatial function of healthy men
(Kampen and Sherwin 1996).
Overall, there is increasing evidence from both
basic science and human studies to indicate that
men with higher levels of serum testosterone
maintain specific domains of cognitive function,
and that administration of testosterone can
enhance selective domains of cognition in men
with lower levels of testosterone. Thus,
supplementation could be a viable therapeutic
option for cognitive deficits generally associated
with healthy aging and neurodegenerative 
diseases. However, findings of prior clinical studies
are preliminary and need to be systematically 
confirmed in larger clinical studies before 
the therapeutic potential of testosterone can be 
firmly established.
TESTOSTERONE AND PROSTATE
One of the greatest fears of supplementing older
men with testosterone is an increased risk for
benign prostate hyperplasia and/or prostate cancer
( Jeyaraj et al. 2000; Guay et al. 2000), two diseases
with high incidence and prevalence in older 
men. Prostate tissue contains large quantities 
of androgen receptor, and the presence of testos-
terone appears to be permissive for development
and progression of both prostate diseases,
although prostate cancer is also found in hypogo-
nadal men (Morgentaler et al. 1996) with rates
comparable to those of the general population.
While prostate cancer is a common diagnosis and
its incidence is increasing (Levi et al. 1998;
La Rosa et al. 2000; Majeed et al. 2000; Brewster
et al. 2000), mortality rates have remained stable
over the years. The 10–15-year survival rates for
localized disease are very high but do not seem to
be affected by treatment (Chodak et al. 1994;
Johansson et al. 1997). It appears that with the
widespread screening for prostate-specific antigen,
we are detecting many prostate cancers that 
would otherwise have remained clinically irrelevant.
Latent prostate cancer is even more common
(Suen et al. 1974; Rullis et al. 1975), as autopsy
series of all ages around the globe give a 
12 percent to 38 percent range (Breslow et al.
1977; Yatani et al. 1982).
Several studies have compared testosterone levels
in prostate cancer patients at the time of diagnosis
with those of age-matched controls (Hulka et al.
1987; Haapiainen et al. 1988; Gustafsson et al.
1996; Schatzl et al. 2000). In all studies, testos-
terone in prostate cancer patients was the same or
lower than that of controls. There are numerous
longitudinal studies on the association of 
testosterone levels with the future risk for prostate 
cancer development (Nomura et al. 1988;
Barrett-Connor et al. 1990; Carter et al. 1995;
Vatten et al. 1997; Heikkila et al. 1999), with 
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surveillance periods of up to 25 years. All studies
except one (Gann et al. 1996) failed to detect any
association. In contrast, an association between
insulin-like growth factor and prostate cancer has
been reported by most studies published recently
(Mantzoros et al. 1997; Shaneyfelt et al. 2000;
Harman et al. 2000). In a rodent model of 
age-dependent prostatic hyperplastic growth, the
susceptible lobes of the prostate showed decreased
rates of cell death and increased proliferation 
in conjunction with increased androgen receptor
levels in old rats relative to young (Banerjee et al.
2000; Banerjee et al. 2001). In apparent contrast
to these results, testosterone repressed tumor
growth when a human prostate cell line was
grown in immunodeficient male mice (Umekita 
et al. 1996; Joly-Pharaboz et al. 2000), although
in one of those studies the tumor eventually 
did regrow even in the presence of androgen.
There are dozens of reports on prospective testos-
terone replacement studies over the last 20 years,
some of which have surveillance periods of up to
6.5 years. No increase in prostate cancer has been
reported in response to testosterone supplementation.
The prostate-specific antigen may rise initially,
appears to plateau later, and generally stays within
normal limits; and the same is true for 
prostate volume. Furthermore, in some studies
prostate volume, prostate-specific antigen,
and urinary tract symptoms actually decreased
(Tenover 1992; Holmang et al. 1993; Wallace et
al. 1993; Douglas et al. 1995; Svetec et al. 1997;
Nieschlag et al. 1999; Snyder et al. 2000; Jin et al.
2001; De Rosa et al. 2001; Pechersky et al. 2002).
The mode of testosterone replacement may 
affect the results. The higher increases of 
prostate-specific antigen and volume were reported 
with parenteral testosterone and appear less 
pronounced or nonexistent in studies utilizing
patch, gel, or oral testosterone undecanoate.
However, no definitive conclusions can be drawn
yet because of methodological shortcomings 
of the studies available to date, including (a) short
duration of follow-up in the vast majority of
them, (b) the highly variable selection of patients
(considering the effects of age, race, and ethnicity
on prostate cancer incidence, trials controlling 
for these factors are needed), and (c) lack of 
standardized method of outcome reporting, e.g.,
different methods are used for prostate volume
estimation, and only a few studies used transrectal
ultrasound and/or biopsies of the prostate 
for assessment.
TESTOSTERONE AND ERECTILE FUNCTION
Testosterone clearly improves libido when 
administered to older men (Morales et al. 1997).
Testosterone is also required for male genital 
differentiation and development, manifestation 
of male secondary sexual characteristics, and 
the initiation and maintenance of spermatogenesis.
Nocturnal penile tumescence and ejaculatory 
volume is also dependent on testosterone. Male-
type libido appears to require more than a 
minimum amount of serum testosterone (Bagatell
et al. 1994). Erectile dysfunction, on the 
other hand, appears to be affected by many factors,
including psychological factors, vascular and
intrinsic penile disease, and autonomic neuropathy,
in addition to hypogonadism. Thus, although 
no direct relationship between hypogonadism and
human erectile dysfunction has been established,
they are both common manifestations of aging
(Korenman et al. 1990).
Explorations of biologic mechanisms underlying
testosterone effects on erectile function come 
primarily from rodent studies. In rats, testosterone
appears to enhance the erectile responses through
regulation of the enzyme nitric oxide synthase.
Because nitric oxide synthase is important 
for stimulating dilation of blood sinuses in erectile
tissues, this action of testosterone could have an
important positive local effect on erectile 
capability. Castration reduces erectile response
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and nitric oxide synthase activity and gene expres-
sion, and either testosterone or dihydrotestos-
terone restores both to normal (Park et al. 1999;
Chamness et al. 1995). The restoration of nitric
oxide synthase activity by testosterone occurs in
penile neurons (Baba et al. 2000) and pelvic 
ganglia, for which 40 percent of nitric oxide 
synthase-containing neurons also contain androgen
receptors (Schirar et al. 1997). A single study has
reported improved responses to sildenafil 
(Viagra) when testosterone is replaced (Tariq et
al. 2003). In comparing erectile responses to
testosterone or dihydrotestosterone, one study
provided evidence that dihydrotestosterone is the
more potent steroid (Park et al. 1999).
TESTOSTERONE, INSULIN SENSITIVITY AND
THE CARDIOVASCULAR SYSTEM 
There are few animal studies focused on the effect
of testosterone on insulin sensitivity and cardio-
vascular function. In one study, insulin sensitivity
in selected muscles was decreased by castration and
restored by testosterone replacement at physiologic
levels, but not by superphysiologic levels of 
testosterone (Holmang and Bjorntorp 1992). This
study did not control for conversion of testos-
terone into estradiol, so it is not clear whether the
effect is attributable entirely to androgenic 
(i.e., androgen receptor-mediated) effects of
testosterone. Regarding the cardiovascular system,
one study reported that either testosterone or
estradiol treatment restored maximal 
serotonin-induced vasodilation in hearts isolated
from castrated male rats (Moyses et al. 2001).
The testosterone effect was probably mediated via
conversion to estrogen because the estrogen 
level in these rats was similar to that seen in naïve
or estrogen-treated castrated females. In a 
low-density lipoprotein receptor-deficient mouse
model of atherogenesis, surgical castration 
accelerates and subsequent testosterone or estradiol
administration retards progression of 
atherosclerosis (Nathan et al. 2001). The effect of
testosterone is antagonized by concomitant use 
of an aromatase inhibitor, suggesting this 
effect of testosterone is also mediated at least in
part by conversion to estradiol in the vessel wall.
In exploring the mechanism of this effect,
Mukherjee et al. (2002) reported that, like estradiol,
an aromatizable androgen such as testosterone,
but not the nonaromatizable androgen dihy-
drotestosterone, inhibits TNF alpha-induced 
vascular cell adhesion molecule-1 expression in
human umbilical vein endothelial cells. Vascular
cell adhesion molecule expression is an early event
in atherogenesis. Testosterone was less effective 
in the presence of an inhibitor of aromatase 
or the estrogen receptor blockers, suggesting that 
estradiol is the active steroid.
Morley (2003) has recently reviewed and summa-
rized the effects of testosterone supplementation
on a wide variety of physiological systems in older
men. In addition to the effects already documented
above, both testosterone and dihydrotestosterone
generally raise insulin-like growth factor levels and
lean body mass while decreasing fat mass. They also
lower serum lipids, including total cholesterol,
high-density lipoprotein and low-density lipoprotein.
Coronary artery disease is associated with low
testosterone levels in men (English et al. 2000) and
short-term supplementation with testosterone has
been used to treat angina, but long-term studies are
needed to determine whether there are any 
deleterious effects on the cardiovascular system.
AGING-RELATED CHANGES 
IN TESTOSTERONE FUNCTION
Most large studies measuring testosterone and
various indices of free or bioavailable testosterone
have concluded that testosterone serum level
declines progressively and monotonically with age
at the rate of about 1 percent per year beginning
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in the fourth decade of life (Figure 1). Observers
agree that by the seventh to eighth decade of 
life, a significant number of otherwise healthy
men have levels of free or bioavailable testosterone
that, if observed in men under the age of 45, would
undoubtedly lead to their classification as 
“hypogonadal.” Whether the fraction qualifying is
40 percent of these men (Morley et al. 2000) or
65 percent (Harman et al. 2001), the fact remains
that the number of such men is substantial and
growing. The extent to which this observed
reduction in testosterone levels contributes to loss 
of bone, lean body/skeletal muscle mass, gain in
body fat, and frailty remains to be determined.
There are relatively few published studies about
this issue. As reviewed above, preliminary evidence
suggests that testosterone replacement has some
potential to reduce these concomitants of aging in
men, but the interactions of testosterone with diet,
exercise, and other hormone deficiencies or excesses 
characteristic of aging are largely unexplored.
THE NEED FOR A LARGE CLINICAL STUDY 
To date, a number of small-scale randomized 
trials of testosterone replacement therapy in older
men have been conducted with reports of positive
effects on bone mineral density, muscle strength,
and body composition; i.e., increase in lean 
body mass and a decrease in fat mass (Wang et al.
2001; Snyder et al. 2000; Snyder et al. 2001;
Blackman et al. 2002). Improvement in certain
aspects of cognition and sense of well-being has
also been reported (Wang et al. 2000). Results
have been variable, and this may well be related to
differences in dosage, route of administration,
and serum concentrations of testosterone
achieved, as well as in the initial degree of 
hypogonadism of the subjects studied. One study 
found that the men with the lowest serum 
testosterone levels showed the largest improve-
ment in bone mineral density. None of the trials
has included a sufficient number of subjects to
adequately assess possible effects on the incidence
of prostate cancer and cardiovascular events.
Given the increasing use of testosterone by the
public, it is crucial to establish the risk/benefit
ratio of testosterone replacement therapy so that
patients and doctors can make informed choices.
A large-scale study with approximately 6,000 
subjects (3,000 taking testosterone with an equal
number taking placebo) has been estimated to 
be necessary to ascertain changes in the incidence 
of prostate cancer and coronary events. This 
number of subjects, based on the need to define
possible risks, should be enough to firmly 
establish the possible benefits of testosterone
replacement therapy.
The need to conduct a large-scale clinical trial is
underscored by the history of hormone replacement
therapy (estrogen plus progesterone) in women.
Decades of epidemiologic research led to wide-
spread use of this treatment for postmenopausal
women. Only recently, as a result of randomized
placebo-controlled, large-scale clinical trials have
we come to believe that the prior interpretation
based on limited epidemiologic data was 
misleading, and the total morbidity attendant to
treatment with hormone replacement therapy 
is increased, not decreased, with greater likelihood
of cardiovascular events and development of
breast cancer [see JAMA 288: 321-333 (2002)].
These data, which could only be attained from 
a large-scale clinical trial, are causing millions of
women and their physicians to reassess the 
wisdom of continuing on hormone replacement
therapy. Similarly, a large-scale clinical trial of
testosterone replacement therapy for older men 
is required to inform men and their physicians
about the risks and benefits of treatment 
with testosterone. The small numbers of older
men who have participated in prior studies are
not sufficient to determine the clinical value of
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this treatment. The study should focus on the
response of older hypogonadal men to an extended
period of testosterone replacement therapy 
(five to six years). Ideally, desirable endpoints to
measure include muscle mass and strength; bone
mineral density and incidence of bone fractures;
body composition; insulin sensitivity, glucose 
tolerance, and incidence of diabetes mellitus;
cognitive function and incidence of dementia;
sense of well-being and incidence of dysthymia;
polycythemia; sleep apnea; progression of 
atherosclerosis; and, most important, the incidence
of cardiovascular events, e.g., myocardial infarction,
stroke, and cardiac death; the development of
benign prostatic hypertrophy requiring invasive
therapy; and the development of clinical prostate
cancer. Some of the major questions about 
how to conduct such a trial have been addressed
in some detail earlier (Bhasin et al. 1998).
RESEARCH AGENDA 
Beyond the need for a large clinical study to
determine whether testosterone supplementation
is both safe and efficacious, a number of other
questions need to be addressed as well.
These questions are briefly discussed below.
Assays for testosterone
Better technology is needed for assaying circulating
levels of testosterone, particularly for clinical 
laboratories. Because testosterone occurs both free
and bound to serum proteins, it is important to 
be able to accurately assay how much is in each
fraction, i.e., free, weakly bound to protein 
and tightly bound to specific sex hormone binding
globulin. Current estimates are that about 
44 percent of circulating testosterone is bound to
sex hormone binding globulin, and the other 
56 percent is either free or loosely bound 
to albumin (Dunn et al. 1981). However, these 
estimates are controversial because assays are 
variable and levels are subject to diurnal variation,
leading to some confusion about what the 
normal ranges are and when an individual could
be considered to be hypogonadal.
An important aspect of this problem is that 
commonly employed assays for “free testosterone”
in commercial laboratories that depend on 
competitive binding of testosterone to ion
exchange resins or glass beads are poorly repro-
ducible and do not correlate well with carefully
conducted measurements of free testosterone 
by dialysis or of bioavailable testosterone by
ammonium sulfate precipitation; even standard 
radioimmunoassay or enzyme-linked immunosor-
bent assay measurement of total testosterone 
in various laboratories has been shown to result 
in significant variation in results obtained on 
replicate samples (Rosner 1997; Winters et al.
1998; Vermeulin et al. 1999; Rosner 2001; Morley
et al. 2002). In the absence of reliable, well-
standardized methodologies for determining
blood levels of testosterone, little progress can be
made in defining age-related hypogonadism
chemically and functionally. If we cannot accurately
determine which men have low biological action
of testosterone based on serum measurements,
it will be impossible to select appropriate 
populations to study for risk/benefit ratios of
testosterone replacement in older men because
baseline testosterone will undoubtedly be a major
determinant of who is likely to benefit.
Screening tests for hypogonadism
Although at least three screening questionnaires
are currently in use to determine whether men 
are functionally hypogonadal, independent 
epidemiological validation of these questionnaires
is lacking. A screening questionnaire based more
on quantifiable symptoms of hypogonadism is
needed. Testosterone measured in saliva shows
that testosterone declines with increasing age
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(Ben-Aryeh et al. 1989; Read et al. 1981). While
salivary testosterone is a proxy for free or weakly
bound testosterone and it may be adequate 
as a screening test, it is not recommended as a
diagnostic test.
Clinical trials
Many earlier clinical trials have suffered from a
variety of methodological shortcomings, including
insufficient numbers of subjects; short duration 
of follow-up; lack of adequate control for effects
of age, race, ethnicity; medication use and illness;
and lack of standardized methods of reporting.
Care must be taken to address all of these issues
in any new clinical trials undertaken. The source
of the androgen also requires careful consideration.
Use of a testosterone gel rather than an injection
is recommended both to avoid large swings 
in testosterone levels leading to nonphysiological
levels and because a gel is the form most likely 
to be used by the public if a trial indicates safety
and efficacy.
Biological studies
Additional research is needed to:
• Identify levels of testosterone that better define
physiological or functional hypogonadism for 
target tissues and organs
• Better understand the relative roles of testos-
terone, dihydrotestosterone, and E2 in mediating
the effects of bioavailable testosterone on these
target tissues and organs
• Determine the number and location of 
androgen receptors in target tissues and organs
and whether these change with age
• Improve our knowledge of age-related changes
in tissue-specific sensitivity and dose response to
testosterone at both the molecular and clinical level.
In general, research is needed to understand the
molecular mechanisms for the effects of 
testosterone on bone mineral density, regional fat
distribution and metabolism, muscle mass and
strength; physical performance and function,
cognitive function and mood, libido and sexual
activity; cardiovascular performance, and immune
function, if any. Studies in the frail elderly 
population are particularly needed.
POLICY ISSUES
In the August 19, 2002, issue of the New York
Times, Gina Kolata (2002) reported that two
agencies of the U.S. government, the Department
of Veterans Affairs and the National Institute on
Aging, had recently announced it would not 
go ahead with a planned 6,000-man clinical trial
to study testosterone replacement therapy in
aging men. This was apparently due to concerns
about whether a clinical trial could be designed
that would protect the study’s subjects from
potential health risks such as prostate cancer, heart
attacks, and strokes. Such concerns are 
consistent with the recent report that estrogen
plus progesterone replacement therapy is not as
safe as originally had been assumed [see JAMA
288: 321–333 (2002)]. However, this raises the
obvious question: How can the medical commu-
nity obtain this information without conducting a
long-term trial?
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ANDROGEN—a generic term for a hormone
that stimulates the activity of the accessory 
sex organs of the male and encourages 
the development of male sex characteristics.
ANDROGEN RECEPTOR—a protein, usually
found in either the cell membrane or in the
nucleus, that binds androgens, thereby stimulating
a variety of cellular responses.
ANDROPAUSE—hormonal changes that 
occur in some men as they age, varying widely in 
intensity and age of onset.
AROMATASE—the enzyme that converts
androgens directly into estrogens.
β-AMYLOID—a small protein normally found
in brain tissue; increased concentrations are 
associated with Alzheimer’s disease.
BENIGN PROSTATE HYPERPLASIA—
a nonmalignant enlargement of the prostate gland.
DIHYDROTESTOSTERONE—a more potent
form of androgen produced from testosterone.
DYSTHYMIA—form of chronic depression.
ESTRADIOL—the most potent naturally 
occurring estrogen in mammals, generated from
testosterone by the enzyme aromatase.
ESTROGEN—a generic term for a hormone
that stimulates the activity of accessory sex organs
of the female and encourages the development 
of female sex characteristics.
GONADOTROPIN—a hormone capable of
promoting growth of the gonads, i.e., sex organs,
produced in the pituitary gland.
GONADOTROPIN RELEASING 
HORMONE—a hormone produced in the
hypothalamus that stimulates production of
gonadotropins by the pituitary gland.
HIPPOCAMPUS—a region of the brain 
associated with memory.
HYPERLIPIDEMIA—an elevated concentra-
tion of lipids in blood.
HYPERTROPHY—overgrowth of a particular
tissue or organ.
HYPOGONADAL—inadequate function of the
gonads, resulting in low androgen levels in blood.
HYPOTHALAMUS—a region of the 
brain involved in function of the autonomic 
nervous system.
INSULIN-LIKE GROWTH FACTOR—
small protein resembling insulin that stimulates
cell growth.
LUTEINIZING HORMONE—a specific 
form of gonadotropin that increases testosterone 
production from the testes.
ORCHIECTOMY—removal of one or both testes.
OSTEOBLAST—bone cells whose function 
is to make new bone.
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OSTEOPOROSIS—disease resulting from 
the reduction in bone density, occurring primarily 
in postmenopausal women and elderly men,
increasing the risk of bone fracture.
POLYCYTHEMIA—an elevated concentration
of red blood cells.
SATELLITE CELLS—stem cells found in
skeletal muscle.
SEX HORMONE BINDING GLOBULIN—
a protein circulating in blood that strongly binds
sex steroid hormones.
SLEEP APNEA—absence of breathing 
during sleep.
TESTOSTERONE—a naturally occurring
androgen in mammals produced primarily in the
testes but also produced in the ovary in females.
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